NEW YORK, July 24 – As part of Applera’s $75 million program to transform itself into a drug discovery and diagnostics powerhouse, company executives for the first time Tuesday discussed in detail how Celera Diagnostics, the newest member of the Applera family, would distinguish itself from its more well-known brethren, Celera Genomics and Applied Biosystems (ABI).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.